Cargando…

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

Neoadjuvant chemotherapy is able to reduce the size of the majority of breast tumours and down-stage axillary-node status. The aim of this study was to assess the prognostic value of persistent node involvement after neoadjuvant chemotherapy. A total of 488 patients with T2–T3, N0–N1 breast cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pierga, J-Y, Mouret, E, Diéras, V, Laurence, V, Beuzeboc, P, Dorval, T, Palangié, T, Jouve, M, Vincent-Salomon, A, Scholl, S, Extra, J-M, Asselain, B, Pouillart, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363409/ https://www.ncbi.nlm.nih.gov/pubmed/11076657 http://dx.doi.org/10.1054/bjoc.2000.1461

Ejemplares similares

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).
por: Pierga, J. Y., et al.
Publicado: (1998)

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.
por: Pierga, J. Y., et al.
Publicado: (1997)

Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer.
por: Scholl, S. M., et al.
Publicado: (1994)

Postirradiation Sarcoma: Clinicopathologic Features and Role of Chemotherapy in the Treatment Strategy
por: des Guetz, Gaetan, et al.
Publicado: (2009)

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)
por: Viens, P, et al.
Publicado: (1999)

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy
por: Baulies, S, et al.
Publicado: (2015)

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2019)

Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma
por: Domenge, C, et al.
Publicado: (2000)

Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial
por: Sabatier, Renaud, et al.
Publicado: (2021)

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings
por: Tartour, E, et al.
Publicado: (2000)

Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer
por: Hamy, Anne-Sophie, et al.
Publicado: (2019)

Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer
por: Pierga, J-Y, et al.
Publicado: (2003)

The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes
por: Laot, Lucie, et al.
Publicado: (2021)

Neoadjuvant Concurrent Radiotherapy and Chemotherapy in Early Breast Cancer Patients: Long-Term Results of a Prospective Phase II Trial
por: Jornet, Diane, et al.
Publicado: (2021)

Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer
por: Jagannathan, N R, et al.
Publicado: (2001)

Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
por: Sugiyama, T, et al.
Publicado: (1999)

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
por: Cottu, P H, et al.
Publicado: (2001)

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
por: Dieras, V., et al.
Publicado: (1996)

Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population
por: Rossi, Lea, et al.
Publicado: (2015)

Adjuvant chemotherapy for colon carcinoma with positive lymph nodes: use and benefit in routine health care practice
por: Bouchardy, C, et al.
Publicado: (2001)

Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study
por: Broët, P, et al.
Publicado: (1999)

Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
por: Zabell, Joseph, et al.
Publicado: (2018)

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
por: Poikonen, P, et al.
Publicado: (1999)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives
por: Beuzeboc, Philippe, et al.
Publicado: (2014)

A prognostic score in histological node negative breast cancer.
por: Chevallier, B., et al.
Publicado: (1990)

Low expression of bcl-2 in Brca1-associated breast cancers
por: Freneaux, P, et al.
Publicado: (2000)

The Role of the Lymph Node Ratio in Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Rawicz-Pruszyński, Karol, et al.
Publicado: (2019)

Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection
por: Jacobsen, K D, et al.
Publicado: (1999)

Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer
por: Ladak, Farah, et al.
Publicado: (2022)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided?
por: Berney, D M, et al.
Publicado: (2001)

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
por: Tartour, E., et al.
Publicado: (1994)

Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive
por: Fishman, Mayer N.
Publicado: (2017)

Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
por: Prakash, Ipshita, et al.
Publicado: (2022)

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
por: Monneur, Audrey, et al.
Publicado: (2017)

Similar biological effects of different low doses of interferon alpha in cancer patients.
por: Billard, C., et al.
Publicado: (1987)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2
por: Scholl, Susy, et al.
Publicado: (2003)

Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes
por: Aragon-Sanchez, Sofia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g0is79mki9u519a4ebot68jug6